Renibus Therapeutics, a Southlake, TX-based clinical-stage biopharmaceutical company, raised an undisclosed amount in Series B extension.
The round, which brought the total Series B round amount to $72M, saw participation from existing and new investors from the cardiac surgery community.
The company intends to use the funds to advance RBT-1 through a pivotal Phase 3 trial for its lead indication of reducing the risk of post-operative complications following cardiothoracic surgery.
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal and metabolic diseases. Its lead program is RBT-1, a drug that will enter a Phase 3 pivotal trial in cardiothoracic surgery in Q4 2023.
In addition, the company is advancing RBT-3, a novel, low molecular weight iron nanoparticle that resolves iron deficiency and may reduces the risk of cisplatin-induced nephrotoxicity, and RBT-9 (stannic protoporfin), an anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties, which It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19.
FinSMEs
12/09/2023